MedPath
HSA Approval

DAFLON FILM-COATED TABLET 1000 mg

SIN15669P

DAFLON FILM-COATED TABLET 1000 mg

DAFLON FILM-COATED TABLET 1000 mg

April 16, 2019

SERVIER (S) PTE LTD

SERVIER (S) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantSERVIER (S) PTE LTD
Licence HolderSERVIER (S) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

**Dosage and method of administration** 3 tablets daily (in 3 divided doses) for 3 to 4 days, then 2 tablets daily (in 2 divided doses).

ORAL

Medical Information

**Therapeutic indications** Treatment of acute hemorrhoidal attacks.

**Contraindications** Do not take Daflon® 1000 if you are allergic (hypersensitive) to micronized purified flavonoid fraction or any of the other ingredients.

C05CA53

diosmin, combinations

Manufacturer Information

SERVIER (S) PTE LTD

LES LABORATORIES SERVIER INDUSTRIE

Active Ingredients

DIOSMIN (MICRONIZED)

900 mg

Diosmin

HESPERIDIN (MICRONIZED)

100 mg

Hesperidin

Documents

Patient Information Leaflets

Daflon tablet 1000mg PIL.pdf

Approved: August 16, 2019

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DAFLON FILM-COATED TABLET 1000 mg - HSA Approval | MedPath